Show
Sort by
-
Reply to Satapathy et al.'s comment on 'Dual cross‐sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014–2022'
-
- Journal Article
- A1
- open access
Dual cross‐sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014–2022
-
Taxonomic and functional profile of the anorectal microbiota in HIV-positive and HIV-negative men who have sex with men, using a metagenomic approach
-
Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real‐world setting in Belgium
-
- Journal Article
- A1
- open access
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV : results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age
-
HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe
-
Mortality under early access to antiretroviral therapy vs Eswatini’s national standard of care : the MaxART clustered randomized stepped‐wedge trial
-
- Journal Article
- A1
- open access
Incidence rate, predictors and outcomes of interruption of HIV care : nationwide results from the Belgian HIV cohort
-
Monitoring PrEP implementation in Belgium : national surveillance results, 2017-2018
-
- Journal Article
- A1
- open access
Predictors of virological failure in HIV-1-infected patients switching to dolutegravir maintenance monotherapy